Battle against superbugs: which antibiotic combo works best?
NCT ID NCT07694700
First seen Jul 10, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study compares two antibiotic combinations—colistin plus meropenem versus amikacin plus meropenem—for treating multi-drug-resistant Gram-negative bacterial infections in intensive care unit patients. The goal is to see which combination is more effective at clearing the infection and improving survival, while also monitoring side effects like kidney function. The trial includes adults aged 18 to 70 admitted to the ICU with these hard-to-treat infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- colistin, meropenem, amikacin
- What this could lead to
- If one combination works better, it could provide a more effective treatment option for dangerous drug-resistant infections in intensive care.
- What could go wrong
- This is a single-center study with 100 participants, so results may not apply broadly. Both antibiotic combinations can cause kidney damage, which is being monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDR BACTERIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beni- Suef University Hospital.
Banī Suwayf, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.